Ularitide: Completed Phase III enrollment

Cardiorentis completed enrollment of 2,157 patients in the double-blind, placebo-controlled, international Phase III TRUE-AHF trial evaluating 15 ng/kg IV ularitide given over 48 hours plus standard o...